E
Enliven Therapeutics, Inc. (ELVN)
NMS – Real vaqt narxi. Valyuta: USD
38.83
-0.46 (-1.17%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
38.25
-0.58 (-1.49%)
Bozordan keyin: Mar 27, 2026, 7:33 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NMS – Real vaqt narxi. Valyuta: USD
38.83
-0.46 (-1.17%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
38.25
-0.58 (-1.49%)
Bozordan keyin: Mar 27, 2026, 7:33 PM EDT
Enliven Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton bilan kasallangan bemorlarga yordam berish uchun kichik molekulyar ingibitorlarni kashf qilish va ishlab chiqishga qaratilgan. Uning klinik dasturlari orasida surunkali miyeloid leykemiya bilan kasallangan kattalarni davolash uchun 1-faza klinik sinovlarida bo'lgan kichik molekulyar kinaza ingibitori ELVN-001; va markaziy asab tizimiga (MS) kirib boradigan va qaytarilmas inson epidermis o'sish omili retseptorlari 2 ingibitori ELVN-002 mavjud bo'lib, u 1-faza klinik sinovlarida mayda hujayrali o'pka saratonini (NSCLC) va boshqa HER2 mutatsiyasiga ega o'smalarni davolash uchun ishlatiladi. Kompaniya 2019 yilda tashkil etilgan va shtab-kvartirasi Kolorado shtatining Bouldr shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Richard A. Fair | CEO, President & Director |
| Mr. Samuel S. Kintz M.B.A. | Co-Founder & Head of Pipeline |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-03 | S-8 | d189577ds8.htm |
| 2026-01-07 | 8-K | d28332d8k.htm |
| 2025-12-16 | S-8 | d63864ds8.htm |
| 2025-12-11 | 8-K | d937094d8k.htm |
| 2025-11-13 | 8-K/A | elvn-20251112.htm |
| 2025-11-12 | 10-Q | elvn-20250930.htm |
| 2025-08-13 | S-3ASR | d42284ds3asr.htm |
| 2025-06-25 | 8-K | d80015d8k.htm |
| 2025-06-16 | 8-K | d150245d8k.htm |
| 2025-06-13 | 8-K | d877944d8k.htm |